First-Line Atezolizumab for Metastatic NSCLC with high PD-L1 expression: A United States-Based Cost-Effectiveness Analysis
figureposted on 2021-04-01, 15:07 authored by Adis Journals on behalf of:, Ye Peng, ,Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.